TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.58M | -31.17M | -27.21M | -30.05M | -55.58M |
| Total Depreciation and Amortization | 693.00K | 712.00K | 741.00K | 744.00K | 745.00K |
| Total Amortization of Deferred Charges | 945.00K | 837.00K | 847.00K | 612.00K | 434.00K |
| Total Other Non-Cash Items | 13.64M | 3.72M | -1.38M | -2.61M | 16.20M |
| Change in Net Operating Assets | 3.07M | -2.48M | -7.47M | -9.55M | -6.11M |
| Cash from Operations | -21.24M | -28.37M | -34.48M | -40.84M | -44.31M |
| Capital Expenditure | -927.00K | -880.00K | -1.03M | -345.00K | -667.00K |
| Sale of Property, Plant, and Equipment | 80.00K | 40.00K | 40.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -1.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 1.00M |
| Cash from Investing | -847.00K | -840.00K | -993.00K | -345.00K | -667.00K |
| Total Debt Issued | 10.00M | 10.00M | 35.00M | 25.00M | 25.00M |
| Total Debt Repaid | -97.00K | -113.00K | -133.00K | -84.00K | -87.00K |
| Issuance of Common Stock | 25.65M | 31.40M | 12.74M | 15.61M | 12.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.07M | -2.07M | -3.11M | -2.59M | -2.61M |
| Cash from Financing | 33.48M | 39.22M | 44.50M | 37.94M | 34.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.40M | 10.01M | 9.03M | -3.25M | -10.00M |